Insiders · NXTC

Sol Langermann

Chief Scientific Officer at NextCure, Inc. (NXTC)

Sol Langermann has filed 6 insider reports with the SEC since March 2021, as chief Scientific Officer at NextCure, Inc. (NXTC). The latest filing, on February 3, 2025, reports grant or award at NextCure, Inc. (NXTC).

Filings
6
Companies
1
Bought on market
None
Sold on market
None

Companies where Sol Langermann is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
NextCure, Inc. logo
NXTC
NextCure, Inc.
Chief Scientific Officer$6.45Feb 3, 2025

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Sol Langermann with

Other insiders at the same companies

Questions about Sol Langermann

What is Sol Langermann's role at NextCure, Inc.?
Sol Langermann reports to the SEC as chief Scientific Officer at NextCure, Inc. (NXTC), according to the latest filing on February 3, 2025.
Has Sol Langermann bought or sold stock recently?
No open-market purchases or sales by Sol Langermann are on file. The filings report grant or award.
How do I get alerts when Sol Langermann files?
Follow Sol Langermann on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Sol Langermann (SEC CIK 0001775459). Totals count each trade once, skipping amendments whose original is on file, from Mar 16, 2021 on. View on SEC EDGAR · Get this as JSON